Intrinsiqs

Is Halozyme Therapeutics, Inc. overvalued?

Halozyme Therapeutics, Inc. (HALO) — key valuation metrics and fundamentals.

No verdict
Price
$76.00
Fair value
Current P/E
Normal P/E
Market cap
$8.93B
Dividend yield
Return on equity
Sector
Healthcare

See the full interactive analysis →

Fair value compares HALO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 29 Jun 2026.